Patent · US Active

Medical use of compound III

US10919898B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Michael Steven SAND · Monroe, US
Holger Rosenbrock · Mittelbiberach, DE
Riccardo Giovannini · Verona, IT
Masashi ADACHI · Mino, JP
Bodo Betzemeier · Biberach an der Riß, DE
Tobias BRODMANN · Hannover, DE
Takayuki KAMATA · Kasai, JP
Yohei KAWABATA · Yamagata, JP
Masanori Ito · Saitama, JP
Daniel MARCKART · Budenheim, DE
Manabu Nakatani · Kasai, JP
Ulrike Werthmann · Biberach an der Riß, DE

Key dates

Filing date	Feb 21, 2018
Grant date	Feb 16, 2021
Priority date	—
Expiry date	Feb 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.